These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23744431)

  • 1. In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent.
    Żołnierczyk JD; Borowiak A; Błoński JZ; Cebula-Obrzut B; Rogalińska M; Kotkowska A; Wawrzyniak E; Smolewski P; Robak T; Kiliańska ZM
    Pharmacol Rep; 2013; 65(2):460-75. PubMed ID: 23744431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia.
    Rogalińska M; Błoński JZ; Góralski P; Wawrzyniak E; Hartman M; Rogalska A; Robak P; Koceva-Chyła A; Piekarski H; Robak T; Kiliańska ZM
    Int J Oncol; 2015 Mar; 46(3):1259-67. PubMed ID: 25572009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
    Zolnierczyk JD; Błoński JZ; Robak T; Kiliańska ZM; Wesierska-Gadek J
    Ann N Y Acad Sci; 2009 Aug; 1171():124-31. PubMed ID: 19723046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.
    Rogalińska M; Błoński JZ; Komina O; Góralski P; Zołnierczyk JD; Piekarski H; Robak T; Kiliańska ZM; Wesierska-Gadek J
    J Cell Biochem; 2010 Jan; 109(1):217-35. PubMed ID: 19911397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.
    Żołnierczyk JD; Komina O; Błoński JZ; Borowiak A; Cebula-Obrzut B; Smolewski P; Robak P; Kiliańska ZM; Węsierska-Gądek J
    Med Oncol; 2012 Sep; 29(3):2111-26. PubMed ID: 22086735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells.
    Kobylinska A; Blonski JZ; Hanausek M; Walaszek Z; Robak T; Kilianska ZM
    Oncol Rep; 2004 Mar; 11(3):699-705. PubMed ID: 14767525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone.
    Kobylinska A; Bednarek J; Blonski JZ; Hanausek M; Walaszek Z; Robak T; Kilianska ZM
    Oncol Rep; 2006 Dec; 16(6):1389-95. PubMed ID: 17089066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
    Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
    J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia.
    Rogalinska M; Goralski P; Wozniak K; Bednarek JD; Blonski JZ; Robak T; Piekarski H; Hanausek M; Walaszek Z; Kilianska ZM
    Leuk Res; 2009 Feb; 33(2):308-14. PubMed ID: 18676014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells.
    Bogusz J; Majchrzak A; Mędra A; Cebula-Obrzut B; Robak T; Smolewski P
    Postepy Hig Med Dosw (Online); 2013 Mar; 67():107-18. PubMed ID: 23475487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising anti-leukemic activity of atorvastatin.
    Żołnierczyk JD; Borowiak A; Hikisz P; Cebula-Obrzut B; Błoński JZ; Smolewski P; Robak T; Kiliańska ZM
    Oncol Rep; 2013 May; 29(5):2065-71. PubMed ID: 23440293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.
    Bellosillo B; Villamor N; Colomer D; Pons G; Montserrat E; Gil J
    Blood; 1999 Oct; 94(8):2836-43. PubMed ID: 10515887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
    Robak P; Linke A; Cebula B; Robak T; Smolewski P
    Leuk Lymphoma; 2006 Dec; 47(12):2625-34. PubMed ID: 17169808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
    Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
    Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.
    Morande PE; Zanetti SR; Borge M; Nannini P; Jancic C; Bezares RF; Bitsmans A; González M; Rodríguez AL; Galmarini CM; Gamberale R; Giordano M
    Invest New Drugs; 2012 Oct; 30(5):1830-40. PubMed ID: 21887502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.
    Rebolleda N; Losada-Fernandez I; Perez-Chacon G; Castejon R; Rosado S; Morado M; Vallejo-Cremades MT; Martinez A; Vargas-Nuñez JA; Perez-Aciego P
    PLoS One; 2016; 11(4):e0154159. PubMed ID: 27101369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
    Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
    Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.
    Shamaa LA; Hussein Ael-S; Balbaa OA; Farahat NM; Ali MA
    Egypt J Immunol; 2008; 15(1):181-92. PubMed ID: 20306682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia.
    Podhorecka M; Halicka D; Klimek P; Kowal M; Chocholska S; Dmoszynska A
    Ann Hematol; 2011 Feb; 90(2):173-83. PubMed ID: 20714724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.